Rod Raynovich | TalkMarkets | Page 1
CEO of Raygent Associates
Contributor's Links: Raygent
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ...more


Latest Posts
1 to 16 of 334 Posts
1 2 3 ... 21
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers.
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling.
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up.
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro factors is our small and mid cap stock picks.
Healthcare Sector Update: MedTech Trending Up
Earnings from major device companies and large-cap biopharma over the next two weeks will help us ascertain risks for the market.
April Is Busting Out For Healthcare And Biotech
Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend.
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of 2023 was quite good overall.
Can Healthcare Stocks Survive Macro Headwinds?
Healthcare stocks are supposed to be defensive plays in a choppy market. However, over the past 18 months, the XLV is flat and down 6% over one year.
Small Cap Biotechs Slammed By SVB Collapse
Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation.
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
SMID Cap Life Science Update: Are You An Investor Or Trader?
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.
1 to 16 of 334 Posts
1 2 3 ... 21